Recent Updates — DNQAF

Semnur Pharmaceuticals, Inc. entered into a binding term sheet with iHolding Group LLP to facilitate a $100,000,000 proposed investment of newly issued common stock at an expected price of $10.00 per share. The transaction, representing approximately 10,000,000 shares, is subject to customary due diligence, board approvals, and stockholder approval. Semnur Pharmaceuticals, Inc. is a biotechnology company focused on developing therapeutic solutions.